Page 15 - IMO-2-3

Innovative Medicines & Omics MSC exosomes for digestive tumors: Bench to bedside

Acknowledgments 5. Li C, Sun Y, Xu W, Chang F, Wang Y, Ding J. Mesenchymal
stem cells-involved strategies for rheumatoid arthritis
None. therapy. Adv Sci (Weinh). 2024;11:e2305116.
Funding doi: 10.1002/advs.202305116

None. 6. Arya S, Collie S, Parent CA. The ins-and-outs of exosome
biogenesis, secretion, and internalization. Trends Cell Biol.
Conflict of interest 2024;34:90-108.
doi: 10.1016/j.tcb.2023.06.006
Ying Liu is an employee of the Sinocelltech Ltd. company.
This has not influenced the content of the manuscript. No 7. Minetti G, Achilli C, Perotti C, Ciana A. Continuous change
reference to the author’s company is made, but it is declared in membrane and membrane-skeleton organization during
for full transparency. Other authors declare no conflict of development from proerythroblast to senescent red blood
interest. cell. Front Physiol. 2018;9:286.
doi: 10.3389/fphys.2018.00286
Author contributions 8. Welsh J, Goberdhan D, O’Driscoll L, et al. Minimal

Conceptualization: Ying Liu information for studies of extracellular vesicles
Visualization: Pengyun Lin (MISEV2023): From basic to advanced approaches.
Writing – original draft: Ying Liu J Extracell Vesicles. 2024;13:e12404.
Writing – review & editing: Tao Zhang doi: 10.1080/20013078.2018.1535750
Ethics approval and consent to participate 9. Lai J, Chau Z, Chen S, et al. Exosome processing and
characterization approaches for research and technology
Not applicable. development. Adv Sci (Weinh). 2022;9:e2103222.
doi: 10.1002/advs.202103222
Consent for publication
10. Jeppesen D, Fenix A, Franklin J, et al. Reassessment of
Not applicable. exosome composition. Cell. 2019;177:428-445.e418.

Availability of data doi: 10.1016/j.cell.2019.02.029
11. Zhang Y, Bi J, Huang J, et al. Exosome: A review of its
Not applicable.
classification, isolation techniques, storage, diagnostic
References and targeted therapy applications. Int J Nanomedicine.
2020;15:6917-6934.
1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics doi: 10.2147/IJN.S264498
2022: GLOBOCAN estimates of incidence and mortality
worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 12. Lee K, Seo E, Lee J, Kim HJ, Hwangbo C. The multifunctional
2024;74:229-263. protein syntenin-1: Regulator of exosome biogenesis,
cellular function, and tumor progression. Int J Mol Sci.
doi: 10.3322/caac.21834 2023;24:9418.
2. Huppert L, Gumusay O, Idossa D, Rugo HS. Systemic doi: 10.3390/ijms24119418
therapy for hormone receptor-positive/human epidermal
growth factor receptor 2-negative early stage and metastatic 13. Han Q, Li W, Hu K, et al. Exosome biogenesis: Machinery,
breast cancer. CA Cancer J Clin. 2023;73:480-515. regulation, and therapeutic implications in cancer. Mol
Cancer. 2022;21:207.
doi: 10.3322/caac.21777
doi: 10.1186/s12943-022-01671-0
3. Zhang T, Lin R, Wu H, Jiang X, Gao J. Mesenchymal stem
cells: A living carrier for active tumor-targeted delivery. Adv 14. Zhu L, Sun H, Wang S, et al. Isolation and characterization of
Drug Deliv Rev. 2022;185(0):137001. exosomes for cancer research. J Hematol Oncol. 2020;13:152.
doi: 10.1016/j.addr.2022.114300 doi: 10.1186/s13045-020-00987-y
4. Barrère-Lemaire S, Vincent A, Jorgensen C, Piot C, Nargeot J, 15. Elhanani O, Ben-Uri R, Keren L. Spatial profiling
Djouad F. Mesenchymal stromal cells for improvement of technologies illuminate the tumor microenvironment.
cardiac function following acute myocardial infarction: Cancer Cell. 2023;41:404-420.
A matter of timing. Physiol Rev. 2023;104:659-725. doi: 10.1016/j.ccell.2023.01.010
doi: 10.1152/physrev.00009.2023 16. Wang J, Hendrix A, Hernot S, et al. Bone marrow stromal

Volume 2 Issue 3 (2025) 9 doi: 10.36922/IMO025210025